CD274 and non-small cell lung carcinoma: Facchinetti et al. recently reported finding that the median progression‐free survival (mPFS) time and median overall survival (mOS) time of advanced‐NSCLC patients with a PS of 2 and high PD‐L1 expression level treated with pembrolizumab monotherapy was 2.4 months and 3.0 months, respectively, and poorer than the results reported by the KEYNOTE‐024 study, which evaluated the efficacy of pembrolizumab monotherapy in treatment‐naïve patients with advanced NSCLC and high PD‐L1 expression.1, 4